Biophytis And Skyepharma Announced A Partnership Agreement For The Production Of Regulatory Batches Of Sarconeos (BIO101) For Severe Forms Of Covid-19, With A View To The Submission Of Marketing Authorization Applications
Portfolio Pulse from Benzinga Newsdesk
Biophytis and Skyepharma have entered into a partnership for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19. The partnership aims to submit marketing authorization applications.
September 25, 2023 | 11:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biophytis has partnered with Skyepharma for the production of Sarconeos (BIO101), which could potentially boost its market position if the marketing authorization applications are successful.
The partnership with Skyepharma for the production of Sarconeos (BIO101) could potentially enhance Biophytis' market position and its stock value, especially if the marketing authorization applications are successful. However, the actual impact will depend on the success of the regulatory approval process and the market acceptance of the product.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100